고효능 원료의약품(HPAPI) 시장 : 분자 유형별, 생산 기술별, 용도별, 지역별
High Potency Active Pharmaceutical Ingredients Market, By Molecule Type, By Production Technology, By Application, By Geography
상품코드
:
1708554
리서치사
:
Coherent Market Insights
발행일
:
2025년 03월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
세계의 고효능 원료의약품(HPAPI) 시장은 2025년에 357억 1,000만 달러에 달하고, 2032년에는 713억 9,000만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지의 연평균 성장률(CAGR)은 10.4%를 나타낼 것으로 전망됩니다.
| 보고 범위 |
보고서 세부정보 |
| 기준 연도 |
2024년 |
시장 규모(2025년) |
357억 1,000만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간 : 2025-2032년 CAGR : |
10.40% |
가치 예측(2032년) |
713억 9,000만 달러 |
그림. 고효능 원료의약품(HPAPI) 시장 점유율(%), 지역별(2025년)
세계의 고효능 원료의약품(HPAPI) 시장은 고활성 의약품의 생산을 전문으로 하는 제약 업계의 중요한 부문으로 구성되어 있습니다. 고효능 원료의약품(HPAPI)은 그 효능과 작용의 특이성에 의해 암, 당뇨병, 자가면역질환 등의 만성적이고 복잡한 건강상태의 치료에 점점 이용되고 있습니다. 이 질병의 유병률이 세계적으로 상승을 계속함에 따라, 고활성 의약품에 대한 수요도 증가하고, 세계의 고효능 원료의약품(HPAPI) 시장을 전진시키고 있습니다. 많은 제조업체는 연구개발(R&D)에 많은 투자를 하고 안전성과 유효성 프로파일을 개선한 새로운 HPAPI를 개발하고 있습니다. 독성을 나타낼 수 있는 고활성 물질을 취급하기 위한 전문 시설이 필요해, 그 결과, 운영상의 큰 과제가 되고 있습니다. 또한, 의약품에 있어서의 기술과 혁신의 진보는 항체 약물 복합체(ADC) 이와 같은 표적 치료 접근법의 개발로 이어지고 있습니다. 강한 세포에 대한 손상이 줄어들고 부작용이 최소화되므로 환자의 결과가 향상됩니다. 개발에의 지속적인 투자, 강력한 규제 프레임워크, 맞춤형 의료의 진전에 의해 헬스케어 분야에 있어서의 HPAPI의 역할은 가까운 미래 대폭으로 확대될 것으로 예측됩니다.
시장 역학 :
세계의 고효능 원료의약품(HPAPI) 시장의 성장은 생물제제나 표적치료제에 대한 수요 증가가 견인하고 있습니다. 홍보 희귀 질병에 대한 희귀 의약품의 개발에 대한 관심 증가는 시험 활동을 뒷받침하고 있습니다.
본 조사의 주요 특징
- 본 보고서에서는 세계의 고효능 원료의약품(HPAPI) 시장을 상세하게 분석하여 2024년을 기준 연도로 한 예측기간(2025-2032년) 시장 규모 및 CAGR을 제공합니다.
- 다양한 부문에서의 잠재적인 수익 성장 기회를 밝히고, 이 시장의 매력적인 투자 제안의 매트릭스에 대해 해설했습니다.
- 또한 시장 성장 촉진요인, 성장 억제요인, 기회, 신제품의 출시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
- 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 파라미터에 근거해, 세계의 고효능 원료의약품(HPAPI) 시장 주요 기업을 프로파일하고 있습니다.
- 본 보고서로부터의 인사이트에 의해 마케팅 담당자나 기업의 경영진은 장래의 제품 출시, 유형 업, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있습니다.
- 세계의 고효능 원료의약품(HPAPI) 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해 관계자에 대응하고 있습니다.
- 이해관계자는 세계의 고효능 원료의약품(HPAPI) 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.
목차
제1장 조사의 목적과 전제조건
제2장 시장 전망
- 보고서 설명
- 주요 요약
- 일관된 기회 맵(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 암이나 기타 만성질환의 이환율 상승
- 높은 생산비용
- 전문의약품 생산 증가
- 주요 하이라이트
- 규제 시나리오
- 최근 동향
- 제품 출시/승인
- PEST 분석
- PORTER 분석
- 합병, 인수 및 제휴
제4장 세계의 고효능 원료의약품(HPAPI) 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
- COVID-19 역학
- 공급측과 수요측의 분석
- 경제에 미치는 영향
제5장 세계의 고효능 원료의약품(HPAPI) 시장, 분자 유형별(2020-2032년)
제6장 세계의 고효능 원료의약품(HPAPI) 시장, 생산 기술별(2020-2032년)
제7장 세계의 고효능 원료의약품(HPAPI) 시장, 용도별(2020-2032년)
제8장 세계의 고효능 원료의약품(HPAPI) 시장, 지역별(2020-2032년)
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제9장 경쟁 구도
- 기업 프로파일
- Lonza
- Novartis International AG
- BASF AG
- SEQENS
- Carbogen Amcis AG
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd
- Bristol-Myers Squibb
- Pfizer Inc.
- Roche Diagnostics
- Boehringer Ingelheim
- Merck &Co
- Bayer AG
- Ajinomoto Bio-Pharma Services
- Cambrex Corporation
- Minakem
- Sanofi Aventis
제10장 섹션
KTH
영문 목차
Global High Potency Active Pharmaceutical Ingredients Market is estimated to be valued at USD 35.71 Bn in 2025 and is expected to reach USD 71.39 Bn by 2032, growing at a compound annual growth rate (CAGR) of 10.4% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 35.71 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
10.40% |
2032 Value Projection: |
USD 71.39 Bn |
Figure. High Potency Active Pharmaceutical Ingredients Market Share (%), By Region 2025
Global high potency active pharmaceutical ingredients (HPAPI) market comprises of a significant segment of the pharmaceutical industry that specializes in the production of highly potent drugs. These ingredients are characterized by their ability to deliver therapeutic effects at low concentrations and their potential to target specific disease cells with precision. High potency active pharmaceutical ingredients (HPAPIs) are increasingly utilized in the treatment of chronic and complicated health conditions such as cancer, diabetes, and autoimmune diseases due to their effectiveness and specificity in action. As the prevalence of these diseases continues to rise globally, so does the demand for high potency medication, propelling the global high potency active pharmaceutical ingredients (HPAPI) market forward. Manufacturers in this sector are investing heavily in research and development (R&D) to create new HPAPIs that offer improved safety and efficacy profiles. The highly regulated nature of this market necessitates stringent containment measures and specialized facilities to handle these potent substances, which can be toxic at certain levels of exposure, thereby presenting significant operational challenges. Moreover, the advancement in technology and innovation in pharmaceuticals is leading to the development of targeted therapy approaches like antibody-drug conjugates (ADCs), where high potency active pharmaceutical ingredients (HPAPIs) are conjugated with monoclonal antibodies to deliver the active compound directly to cancer cells. This precision reduces damage to healthy cells and minimizes side effects, thereby enhancing patient outcomes. Global high potency active pharmaceutical ingredients (HPAPI) market is a dynamic and evolving field that holds substantial promise for the effective management of complex medical conditions. With continued investment in development, strong regulatory frameworks, and the advancement of personalized medicine, its role in the healthcare sector is expected to expand significantly in the near future.
Market Dynamics:
The growth of the global high potency active pharmaceutical ingredients market is driven by the increasing demand for biologics and targeted therapies. Rising prevalence of chronic diseases like cancer is propelling the demand for biologics with higher potency and specificity. Growing focus on the development of orphan drugs for rare medical conditions is boosting trial activities. This is expected to positively impact the global high potency active pharmaceutical ingredients (HPAPI) market.
Key Features of the Study:
- This report provides an in-depth analysis of the global high potency active pharmaceutical ingredients market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global high potency active pharmaceutical ingredients market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Lonza, Novartis International AG, BASF AG, SEQENS, Carbogen Amcis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb, Pfizer Inc., Roche Diagnostics, Boehringer Ingelheim, Merck & Co, Bayer AG, Ajinomoto Bio-Pharma Services, Cambrex Corporation, Minakem, and Sanofi Aventis
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up gradation, market expansion, and marketing tactics
- Global high potency active pharmaceutical ingredients market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global high potency active pharmaceutical ingredients market
Detailed Segmentation:
- Global High Potency Active Pharmaceutical Ingredients Market, By Molecule Type
- Global High Potency Active Pharmaceutical Ingredients Market, By Production Technology
- Chemical Synthesis
- Biotechnology
- Global High Potency Active Pharmaceutical Ingredients Market, By Application
- Oncology
- Hormonal
- Glaucoma
- Others
- Global High Potency Active Pharmaceutical Ingredients Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles
- Lonza
- Novartis International AG
- BASF AG
- SEQENS
- Carbogen Amcis AG
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd
- Bristol-Myers Squibb
- Pfizer Inc.
- Roche Diagnostics
- Boehringer Ingelheim
- Merck & Co
- Bayer AG
- Ajinomoto Bio-Pharma Services
- Cambrex Corporation
- Minakem
- Sanofi Aventis
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market High Potency Active Pharmaceutical Ingredients, By Molecule Type
- Market High Potency Active Pharmaceutical Ingredients, By Production Technology
- Market High Potency Active Pharmaceutical Ingredients, By Application
- Market High Potency Active Pharmaceutical Ingredients, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rising prevalence of cancer and other chronic diseases
- High cost of production
- Increased production of specialty drugs
- Key Highlights
- Regulatory Scenario
- Recent Trends
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, and Collaborations
4. Global High Potency Active Pharmaceutical Ingredients Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global High Potency Active Pharmaceutical Ingredients Market, By Molecule Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Innovative
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
6. Global High Potency Active Pharmaceutical Ingredients Market, By Production Technology, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Chemical Synthesis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Biotechnology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
7. Global High Potency Active Pharmaceutical Ingredients Market, By Application, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Hormonal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Glaucoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
8. Global High Potency Active Pharmaceutical Ingredients Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Molecule Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Production Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Molecule Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Production Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Molecule Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Production Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Molecule Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Production Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Molecule Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Production Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Molecule Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Production Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
- South Africa
- Central Africa
- North Africa
9. Competitive Landscape
- Company Profile
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Roche Diagnostics
- Boehringer Ingelheim
- Merck & Co
- Bayer AG
- Ajinomoto Bio-Pharma Services
- Cambrex Corporation
- Minakem
- Sanofi Aventis
- Analyst Views
10. Section
- References
- Research Methodology
- About us
관련자료
